Compounds and uses thereof for the modulation of hemoglobin
US-2016031865-A1 · Feb 4, 2016 · US
US10017491B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10017491-B2 |
| Application number | US-201715445878-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 28, 2017 |
| Priority date | Mar 15, 2013 |
| Publication date | Jul 10, 2018 |
| Grant date | Jul 10, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
Opening claim text (preview).
What is claimed is: 1. A pharmaceutical composition comprising a compound having the structure: and a pharmaceutically acceptable excipient.
Non condensed piperidines, e.g. piperocaine · CPC title
1,4-Oxazines, e.g. morpholine · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms · CPC title
Drugs for disorders of the blood or the extracellular fluid · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.